Position in LYEL
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$839,459
+$788,457 QoQ
Shares Held
59,748
+3505.8% QoQ
Ownership
0.244%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#27
of 87 holders
Holding Since
Mar 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ACADIAN ASSET MANAGEMENT LLC holds $732,389,014 across 168 Biotechnology names. LYEL ranks #71 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
1,664,999 | $188,744,286 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
157,440 | $98,170,137 | |
| 3 | IMCR |
Immunocore Holdings plc
|
1,209,894 | $38,414,134 | |
| 4 | RIGL |
Rigel Pharmaceuticals Inc
|
591,686 | $23,146,756 | |
| 5 | EXEL |
Exelixis, Inc.
|
421,444 | $22,930,768 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
42,122 | $20,923,261 | |
| 7 | TBPH |
Theravance Biopharma, Inc.
|
1,174,910 | $19,973,470 | |
| 8 | PRTA |
Prothena Corp Public Ltd Co
|
2,010,645 | $19,684,214 |
All Filings in LYEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $839,459 | 59,748 | Shares | Defined | 2026-08-13 | |
| 2025-12-31 | $51,002 | 1,657 | Shares | Defined | 2026-02-10 | |
| 2025-09-30 | $184,973 | 11,390 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $241,915 | 27,366 | Shares | Defined | 2025-08-07 | |
| 2025-03-31 | $355,563 | 660,899 | Shares | Defined | 2025-05-21 | |
| 2024-12-31 | $139,062 | 217,285 | Shares | Defined | 2025-02-11 | |
| 2024-03-31 | $173,832 | 77,952 | Shares | Defined | 2024-05-10 | |
| No filing history on record for this holder in this stock. | ||||||